Wen-Hung Chen, AstraZeneca

Lori D. McLeod, RTI Health Solutions

Globally, regulatory and health technology assessment (HTA) bodies recognise the importance of hearing from patients when products are being developed and evaluated. Patient-reported outcomes and other clinical outcome assessments are increasingly included in submissions to these bodies. Additionally, recent regulatory guidance also discusses the collection of patient preference information. This broader conceptualisation can be termed 'patient experience data' (PED).

Despite this recognition, patient experience data are inconsistently included and evaluated by decision-makers. Understanding how different interest-holders approach this is essential for ensuring that patients' voices drive healthcare decisions to ultimately improve patient outcomes and health-related quality of life.

This article collection encourages submissions that consider the assessment of patient experience, such as preference, symptoms, and health-related quality of life, to inform regulatory and HTA submissions and decisions. Submissions of original research, reviews and discussion and/or response papers addressing recent regulatory and HTA developments in the field are encouraged. Other potential topics for manuscripts may include the application of artificial intelligence and digital health technology in patient experience data research.

Potential topics

• Assessment of patient experience, preference, symptoms, and health-related quality of life to inform regulatory and HTA submissions and decisions
• Original research on patient-reported outcomes and clinical outcome assessments in regulatory submissions
• Patient preference information collection and evaluation
• Reviews and discussion papers addressing recent regulatory and HTA developments in patient experience data
• Application of artificial intelligence and digital health technology in patient experience data research

Timeline

• June 30, 2027: Submission deadline